5 candidates this week — 4 European, 1 US. Ranked by conviction. Buffett/Munger filter: durable moat, rational management, real margin of safety. No momentum names forced onto the list.
Primary hunting ground per mandate. Ranked by conviction, highest first.
Diversified global pharma — immunology (Dupixent), vaccines, rare disease, general medicines.
Why mispriced: Market is pricing in Dupixent's 2031 patent cliff (~half of Q2 revenue) as if it hits tomorrow, compounded by recent pipeline trial failures (Kymab/atopic dermatitis, tolebrutinib setbacks) that spooked sell-side (UBS cut to Neutral). Trailing P/E 18.8x vs forward 8.5x signals the market is discounting near-term earnings heavily — a 5-year runway to patent expiry is being treated as an immediate cliff. Diversified vaccines and immunology pipeline provide a real, underpriced offset.
Dupixent concentration risk is real, not manufactured — replacing ~$13-14bn of high-margin revenue is genuinely hard, and Sanofi's own pipeline replacement bets (Kymab, tolebrutinib) have already stumbled twice. If R&D productivity stays weak into the early 2030s, today's "cheap" multiple could be a value trap, not a bargain.
Niche filtration/separation technology for aerospace, lab, and metal-melt-quality markets — sticky, high-switching-cost end markets.
Why mispriced: Activist investor Richard Bernstein (ex-Crystal Amber) publicly called on Porvair's board in May 2026 to explore a sale, arguing the market values the business "substantially below its strategic value" — a real catalyst, not just cheap-on-a-screener. Niche filtration moat (specified into customer processes, high switching costs) is under-followed given the sub-£350m cap.
Bernstein's stake is small and personal, not a fund with real leverage over the board — this could simply be noise that fades with no sale ever materializing. At 19-21x earnings the stock isn't statistically cheap; the thesis rests entirely on the takeout/re-rating catalyst actually happening.
World's largest dialysis provider — recurring, non-discretionary treatment revenue with entrenched clinic network.
Why mispriced: Trades at 11.7x earnings vs a ~20x healthcare-sector average and ~26x peer average, with Morningstar's fair value estimate implying roughly 39% below intrinsic value. Narrow-but-real moat (clinic density, payer relationships, non-discretionary treatment) mispriced as a "stalled growth story" during a 2026 transition year — the kind of temporary sentiment overhang the mandate looks for.
This is explicitly a narrow moat, not wide — US treatment volume growth has been weak, and margin recovery has "merely stalled, not resumed" per recent coverage. If the transition-year story becomes a multi-year one, the 11.7x multiple could be a fair reflection of structurally slower growth, not a bargain.
Berlusconi-family-controlled broadcaster (Mediaset Italy + Mediaset España) that just took majority control (75.6%) of Germany's ProSiebenSat.1 — a pan-European consolidation special situation.
Why mispriced: Market appears to be discounting integration risk and structural TV-ad decline more than the consolidation math (cost synergies across three national broadcasters, ProSieben scale) justifies. Sum-of-the-parts / DCF estimates put fair value ~40% above the current price. Genuinely underfollowed — cross-border broadcaster consolidation doesn't screen cleanly for most quant models.
Reported a €26.1m net loss in Q1 2026 despite the P7S1 consolidation lifting revenue — integration costs and net debt are real and rising. Family control (Berlusconi/Fininvest) means minority-holder governance risk, and linear TV advertising is a genuine secular-decline business, not just a sentiment overhang. This is a special situation that could easily stay cheap for years if synergies disappoint.
Secondary bucket per mandate — only included where Europe didn't clear the bar on its own.
Largest US health insurer plus Optum (PBM, data, care delivery) — scale moat across claims data and provider relationships.
Why it's on the list at all: Real scale moat, and the DOJ Medicare Advantage billing investigation plus the OptumRx/FTC insulin-rebate matter remain open, keeping a regulatory discount in the multiple versus its own history. A finalized 3% Medicare Advantage rate increase for 2027 removed one major fear.
The easy money is gone. Berkshire built a ~$1.6bn stake in August 2025 near the $271 low and fully exited in Q1 2026 after the stock rallied 45% to ~$394-407. Buying now means paying up for the same regulatory overhang Berkshire's team decided to walk away from. This is a "wait for the next flush" name, not a current buy.